



Erasca Expands Leadership Team with Key Regulatory and Clinical Appointments

06.16.2020

Bao Truong Appointed Vice President of Regulatory Affairs

David Luo Appointed Vice President of Clinical Research and Operations

SAN DIEGO, June 16, 2020 – Erasca, a company whose mission is to erase cancer, today announced the expansion of its leadership team with the appointment of Bao Truong as vice president of regulatory affairs and David Luo as vice president of clinical research and operations.

"We are delighted to continue attracting top talent to Erasca, and the timing is ideal for Bao and Dave to join us, as we rapidly advance multiple pre-clinical programs toward the clinic," said Jonathan E. Lim, M.D., Erasca's chairman, CEO and co-founder. "Having worked closely with both Bao and Dave at Ignyta, I am confident that their strong domain expertise and track records of success in oncology drug development will benefit Erasca as we strive to achieve our ambitious goal of erasing cancer."

About Ms. Truong

Ms. Truong brings 15 years of regulatory experience in oncology product development, ranging from pre-IND through registration phase. Prior to Erasca, Ms. Truong was head of regulatory affairs at IDEAYA Biosciences. Before that, she was head of regulatory affairs at Ignyta, where she helped drive the development plan for Rozlytrek[®] from Phase 1 to registration-enabling Phase 2, supporting both tissue-specific and tissue-agnostic indications. She was previously head of regulatory affairs at Seragon Pharmaceuticals and Aragon Pharmaceuticals, where she helped advance the development of Erleada[®], the first FDA-approved therapy for non-metastatic castration-resistant prostate cancer using a novel clinical endpoint. She also held regulatory lead positions of increasing responsibility at Genentech for multiple oncology products, including Erivedge[®], the first FDA-approved therapy for advanced basal cell carcinoma, Kadcyla[®], Gazyva[®], Tarceva[®] and Herceptin[®]. Earlier in her career, Ms. Truong worked in oncology research at the University of California, San Diego and the University of California, San Francisco. She earned her B.S. in biochemistry from the University of California, San Diego.

About Mr. Luo

Mr. Luo brings 20 years of early- and late-stage drug development experience across multiple therapeutic areas, with a particular emphasis in oncology. Before Erasca, Mr. Luo was vice president of clinical operations at Synthorx, a San Diego biotechnology company acquired by Sanofi, where he was responsible for clinical development and operations of its lead immuno-oncology biologic therapy. Prior to this, he served as vice president of clinical operations at Ignyta, a precision oncology company acquired by Roche, where he led operational oversight of multiple clinical-stage oncology programs, including its lead targeted therapy, Rozlytrek[®], which has been approved in the US, Japan and other territories. Prior to Ignyta, Mr. Luo held multiple leadership positions within clinical research operations at pharmaceutical and biotechnology companies, including Elevation Pharmaceuticals (acquired by Sunovion Pharmaceuticals) and Meritage Pharma (acquired by Shire). Mr. Luo earned a master of public health with an emphasis in toxicology and environmental health sciences from the University of California, Los Angeles and a B.S. in biology from the University of California, San Diego.

About Erasca

At Erasca, our mission is embedded in our name: **To erase cancer**. Energized by recent scientific discoveries in drugging various biological drivers of cancer, we are advancing multiple programs that shut down key cancer pathways in order to solve oncology's hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. We also are pursuing additional pipeline expansion opportunities through academic and biopharmaceutical collaborations. Founded in 2018 and headquartered in San Diego, Erasca has raised more than \$260 million in financing from investors who share the company's bold mission, including ARCH Venture Partners, City Hill Ventures and Cormorant Asset Management. For more information, please visit www.erasca.com.

Erasca is a trademark of Erasca, Inc.

Contact

Heidi Chokeir, Ph.D.
Managing Director
Canale Communications
619-203-5391
heidi@canalecomm.com